KalVista Pharmaceuticals's revenue for the
three
months ended in Oct. 2024 was €0.00 Mil.
Its revenue for the trailing twelve months (TTM) ended in Oct. 2024 was €0.00 Mil.
KalVista Pharmaceuticals's Revenue per Share for the
three
months ended in Oct. 2024 was €0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Oct. 2024 was €0.00.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, KalVista Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 128.90% per year. The lowest was -50.90% per year. And the median was 39.05% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of KalVista Pharmaceuticals's Revenue
For the Biotechnology subindustry, KalVista Pharmaceuticals's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
KalVista Pharmaceuticals's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, KalVista Pharmaceuticals's Revenue distribution charts can be found below:
* The bar in red indicates where KalVista Pharmaceuticals's Revenue falls into.
KalVista Pharmaceuticals Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Oct. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
KalVista Pharmaceuticals Revenue Related Terms
Thank you for viewing the detailed overview of KalVista Pharmaceuticals's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:4XC1 has been successfully added to your 